Novo Nordisk (NYSE: NVO) shares fell nearly 2% on Monday, trading at $46.60, as investors weighed a promising pediatric semaglutide result against two significant clinical setbacks.

Reuters reported that Novo halted two ziltivekimab heart-failure trials, delivering another blow to the company’s efforts to build a diversified growth portfolio beyond its core diabetes and obesity franchise.

The cancellations underscore how difficult it has proven for Novo to establish a reliable second engine of growth, even as its flagship semaglutide treatment continues to generate compelling clinical data.

On the positive side, results from the STEP Young trial offered meaningful evidence that semaglutide could expand into a younger patient population, potentially opening a significant new commercial avenue for the company.

The STEP Young trial enrolled 165 children aged 6 to under 12, tracking outcomes over a 68-week treatment period with both drug and placebo groups receiving diet and exercise support.

After 68 weeks, 40.4% of semaglutide patients dropped below the obesity threshold, compared with zero placebo recipients, under conditions assuming full adherence to the treatment protocol.

More than 85% of trial participants entered the study with severe obesity, and Novo reported no new concerns involving growth or puberty among children receiving semaglutide during the trial period.

The pediatric result broadens semaglutide’s scientific reach considerably, though detailed regulatory submissions, formal clearance, and demonstrated long-term patient persistence will ultimately determine whether the data translates into commercial expansion.

Novo generated DKK33.39 billion in adjusted second-quarter operating profit from DKK78.49 billion in revenue, producing a 42.5% operating margin that gives the company substantial financial capacity to absorb failed experiments.

At $46.60, the stock sits 55.98% below its $105.85 GF Value, a gap that suggests a considerable degree of market pessimism is already embedded in the current share price.

The investment case for Novo remains pulled in opposite directions, with durable semaglutide momentum on one side and a narrowing pipeline of diversification candidates on the other.

Investors will be watching closely for further regulatory developments on the pediatric obesity front, as well as any updates on how Novo plans to rebuild confidence in its broader clinical pipeline following the ziltivekimab withdrawals.